INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 188 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $756,000 | -8.4% | 13,248 | -1.8% | 0.08% | +4.1% |
| Q1 2022 | $825,000 | +16.2% | 13,489 | -0.6% | 0.07% | +7.2% |
| Q4 2021 | $710,000 | +149.1% | 13,568 | +77.6% | 0.07% | +146.4% |
| Q3 2021 | $285,000 | -7.8% | 7,640 | +0.9% | 0.03% | -3.4% |
| Q2 2021 | $309,000 | +10.8% | 7,570 | -8.0% | 0.03% | -6.5% |
| Q1 2021 | $279,000 | +37.4% | 8,229 | +29.1% | 0.03% | +34.8% |
| Q4 2020 | $203,000 | – | 6,373 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |